DeepRhythmAI

by Medicalgorithmics  · Based in Poland → — AI-powered and noninvasive solutions for cardiac diagnostics
Cardiology
Website Contact
Claim this tool
Is this the maker? Claim the company →

Contact vendor for pricing information
Regulatory Status Disclosed

Overview

DeepRhythmAI (DRAI) by Medicalgorithmics S.A. is a cutting-edge, cloud-based artificial intelligence solution designed to significantly enhance the accuracy and efficiency of cardiac arrhythmia detection and classification from electrocardiogram (ECG) data. This device-agnostic platform leverages advanced deep learning techniques, including Convolutional Neural Networks (CNNs) and Transformer models, to analyze multichannel ECG signals with unparalleled precision.

Trained on an extensive dataset of over 250 billion annotated heartbeats, DeepRhythmAI demonstrates superior performance compared to traditional manual analysis. Independent studies have shown that DRAI can reduce the risk of missed clinically meaningful rhythm disturbances by 14 to 114 times, directly impacting patient safety and diagnostic reliability. It is capable of identifying a wide spectrum of arrhythmias, such as atrial fibrillation, ventricular tachycardia, complete heart block, and pauses, providing physicians with comprehensive and reliable insights.

DeepRhythmAI is engineered to streamline clinical workflows, potentially reducing the workload for ECG technicians by up to 65% and enabling faster diagnoses. Its architecture supports seamless integration with existing healthcare systems and various ECG monitoring devices, including Holter, Extended Holter, Event Monitoring, and Mobile Cardiac Telemetry. The platform offers direct-to-physician reporting capabilities, making it a powerful advisory tool for qualified healthcare professionals in conjunction with their clinical expertise and patient history.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered arrhythmia detection and classification
  • Utilizes CNN and Transformer models
  • Trained on 250 billion+ annotated heartbeats
  • Device-agnostic and integrates with various ECG devices
  • Cloud-based software
  • Faster ECG reporting and analysis
  • Reduces missed diagnoses (14x to 114x fewer)
  • Streamlines clinical workflows (up to 65% efficiency increase)
  • Direct-to-physician reporting capabilities
  • Scalable Application Programming Interface (API) for integration

Use Cases

  • Autonomous analysis of ambulatory ECGs
  • Detection of critical arrhythmias (e.g., atrial fibrillation, complete heart block, ventricular tachycardia)
  • Support for Holter, Extended Holter, Event Monitoring, and Mobile Cardiac Telemetry data analysis
  • Predicting atrial fibrillation risk
  • Reducing technician workload in ECG analysis
  • Improving patient safety through enhanced diagnostic accuracy

What Physicians Need to Know

ECG/EKG Analysis Capability
DeepRhythmAI (DRAI) is an FDA-cleared, cloud-based AI algorithm designed for automated analysis of ECG data from adult patients. It processes single- or two-lead ECG data from various devices like Holter, Event recorders, and Mobile Cardiac Telemetry. The system classifies heartbeats as correct or arrhythmic and can recognize a broad array of arrhythmias. DRAI uses CNN and transformer models, trained on a dataset of 250 billion annotated heartbeats, to identify subtle patterns indicative of arrhythmias.
Cardiac CT/MRI Analysis
Medicalgorithmics also develops Virtual Cardiac Stress Test (VCAST), an advanced CT-based cardiac diagnostics software for assessing the hemodynamic significance of coronary lesions. This AI-powered software performs segmentation and reconstruction of coronary vessels from cardiac CT data to non-invasively diagnose coronary artery disease.
Arrhythmia Detection Accuracy
DeepRhythmAI has demonstrated superior accuracy in detecting critical arrhythmias, including atrial fibrillation, complete heart block, pauses, supraventricular, and ventricular tachycardia. Studies show DRAI reduces missed arrhythmia diagnoses by 14 times compared to human analysis, with a false negative rate of 3.2 per 1000 patients versus 44.3 per 1000 patients with technician analysis. It boasts a 99.9% negative predictive value for ruling out critical arrhythmias on ambulatory ECG. For indication-relevant arrhythmias, DRAI achieved sensitivities of 99.5% for tachyarrhythmias and 99.4% for syncope/bradycardia, significantly outperforming ECG technicians.
Heart Failure Risk Prediction
The DeepRhythmAI platform can predict the likelihood of atrial fibrillation. Research using data from 24-hour ECG monitoring with PocketECG devices showed that DRAI could predict the chance of developing atrial fibrillation over a 30-day period.
Coronary Artery Assessment
Medicalgorithmics offers Virtual Cardiac Stress Test (VCAST), an AI-powered software that uses cardiac CT data for non-invasive diagnosis of coronary artery disease by assessing coronary lesions.
Cardiac Monitoring Integration
DeepRhythmAI is designed for integration with third-party software and devices. It can be integrated into medical devices and electronically interfaced with other computer-based ECG systems, such as ECG management systems. DRAI supports downloading and analyzing data from various ECG devices, including Holter, Event recorders, and Outpatient Cardiac Telemetry devices.
Physician Tip

DeepRhythmAI offers a robust AI-powered solution for ECG analysis, significantly enhancing arrhythmia detection accuracy and reducing the burden of manual review. Physicians can leverage its high negative predictive value to confidently rule out critical arrhythmias, streamlining diagnostic workflows. The platform's ability to integrate with various cardiac monitoring devices and systems allows for flexible implementation in diverse clinical settings. While DRAI provides highly accurate analysis, clinical interpretation should always be done in conjunction with the physician's comprehensive understanding of the patient's clinical history and other diagnostic information.

DeepRhythmAI is designed as a cloud-based solution with a scalable Application Programming Interface (API) for easy integration with other medical products and third-party software. It can be integrated into various ECG devices and interfaced with existing ECG management systems. Medicalgorithmics has strategic agreements to integrate DRAI into partner cardiac monitoring ecosystems, expanding its reach within the U.S. and other markets.

Details

Category Cardiology AI, Clinical Decision Support & Reference
Pricing Contact vendor for pricing information
DeploymentCloud-based, hardware-agnostic, SaaS, on-prem, hybrid
Mobile AppYes
API Available Yes
Data Export Yes
Training Yes
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated
SOC 2 Yes AI-estimated
GDPR Yes AI-estimated
Integrations
EHR Not specified
Specialties Cardiology

Support & Reliability

Training Provided Yes

What the Web Says

DeepRhythmAI by Medicalgorithmics is an FDA-cleared, cloud-based AI algorithm designed for the autonomous analysis of single- or two-lead ECG data from adult patients to detect and classify cardiac arrhythmias. It integrates with various ECG devices and existing healthcare workflows, aiming to improve diagnostic accuracy and efficiency. Studies have shown that DeepRhythmAI significantly reduces missed diagnoses of critical arrhythmias compared to human technicians, though it may have a slightly higher rate of false positives.

Overall: Positive

Strengths

  • Significantly reduces missed diagnoses of severe arrhythmias (up to 14 times fewer missed diagnoses compared to human technicians).
  • High sensitivity for detecting critical arrhythmias, including atrial fibrillation, complete heart block, and ventricular tachycardia.
  • Can streamline clinical workflows by up to 65%, leading to lower healthcare costs and faster diagnoses.
  • Cloud-based solution with a scalable API for easy integration with other medical products and devices.
  • Analyzes every heartbeat with consistent precision and is not subject to fatigue or cognitive overload.
  • FDA-cleared and trained on a vast dataset of annotated heartbeats.

Limitations

  • May result in a modest increase in false positives compared to human analysis, which would still require physician review.
  • Interpretation results are not intended to be the sole means of diagnosis and require review by qualified healthcare professionals.
  • Not for use in life-supporting or sustaining systems or ECG alarm devices.
  • DeepRhythmAI does not have a user interface and needs to be integrated with external visualization software.

Based on reviews from: fda.gov, lu.se, medicalgorithmics.com, sca-aware.org, phri.ca, springernature.com, scribd.com, healthaidb.com, nih.gov, neutigers.ai

Last updated: 2026-11-01

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate DeepRhythmAI

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

medicalgorithmics.com
Medicalgorithmics' DeepRhythmAI (DRAI), Revolutionizes Heart Diagnosis: 14x Fewer Missed Diagnoses of critical arrhythmias. A clear path to direct-to-physician reporting of ambulatory ECG results, reveals a recent Nature Medicine publication.
Medicalgorithmics announced the publication of independent research in Nature Medicine demonstrating DeepRhythmAI's superior performance in diagnosing cardiac arrhythmias, leading to 14 times fewer missed diagnoses of critical arrhythmias. The study suggests a clear path to direct-to-physician reporting of ambulatory ECG results, streamlining clinical workflows and improving patient outcomes.
2025-02
eurekalert.org
AI is better than humans at analyzing long-term ECG recordings
A study published in Nature Medicine found that DeepRhythmAI, an AI algorithm developed by Medicalgorithmics, led to 14 times fewer missed diagnoses of severe arrhythmias compared to human technicians when analyzing long-term ECG recordings. The research suggests that AI could address the global shortage of healthcare workers capable of interpreting such data.
2025-02
medicalgorithmics.com
New, groundbreaking results from the DRAI MARTINI study: the risk of failing to detect a clinically meaningful rhythm disturbances reduced 75 to 114 times by DeepRhythmAI analysis
The DRAI MARTINI study revealed that Medicalgorithmics' DeepRhythmAI algorithm significantly outperforms ECG technicians in detecting clinically relevant arrhythmias, reducing the risk of missed diagnoses by 75 to 114 times depending on the patient group. This improved effectiveness translates to better patient care and reduced healthcare costs.
2025-11
medicalgorithmics.com
Medicalgorithmics has achieved another milestone. Certification for its DeepRhythm Platform in Canada.
Medicalgorithmics' DeepRhythm Platform (DRP), integrated with DeepRhythmAI, has received Health Canada registration, allowing its commercial implementation in the Canadian market. This follows earlier regulatory approvals in the U.S. (FDA) and Europe (CE) for both the DRP and DRAI algorithms.
2024-10
medicalgorithmics.com
Medicalgorithmics Receives FDA Approval for Commercialization of New Arrhythmia Diagnostics Platform in the USA
Medicalgorithmics announced FDA approval for its new cloud-based arrhythmia diagnostics platform, DeepRhythm Platform (DRP), for commercialization in the USA. The DRP, powered by DeepRhythmAI algorithms, had previously received CE certification and FDA approval for the algorithms themselves in 2022.
2024-06
practical-patient-care.com
Medicalgorithmics' DRAI tool detects arrhythmia better than human readers, says study
A study presented at the ESC Congress 2024, dubbed DRAI MARTINI, demonstrated that Medicalgorithmics' DeepRhythmAI (DRAI) algorithm is superior to human specialists in detecting heart rhythm disorders on long ECG recordings. The study found that traditional methods missed diagnoses 14 times more often than DRAI.
2024-09
medicalgorithmics.com
DeepRhythmAI (DRAI) obtains Health Canada registration
Medicalgorithmics announced that its DeepRhythmAI (DRAI) algorithms have obtained Health Canada registration, following U.S. FDA and European CE certifications. This approval allows the advanced AI algorithms for ECG analysis to be used in Canada, a key market for the company.
2024-10
medicalgorithmics.com
Medicalgorithmics ends the year with record 74% revenue growth and positive EBITDA in Q4 2025
Medicalgorithmics reported significant financial growth in Q4 2025, with a 74% year-on-year revenue increase. The company highlighted the impact of the Nature publication on DeepRhythmAI, which enhanced credibility and led to new customer acquisitions, including a contract with Wellysis.
2026-01

Videos

Product demos, reviews, and walkthroughs for DeepRhythmAI.

Loading videos...

View all on YouTube

Frequently Asked Questions

DeepRhythmAI utilizes advanced AI algorithms, including CNN and transformer models, trained on a vast dataset of over 250 billion annotated heartbeats, to analyze ECG data. This allows it to detect and classify 26 types of arrhythmias with significantly higher sensitivity and accuracy than human technicians, reducing missed diagnoses by up to 14 times.
DeepRhythmAI algorithms are FDA-cleared in the USA since 2022 and received CE certification in early June 2024, allowing for commercial deployment in the U.S. and EU markets.
DeepRhythmAI is a cloud-based solution that can integrate with third-party software and devices through a scalable Application Programming Interface (API). It is designed to streamline workflows, provide direct-to-physician reporting of ambulatory ECG results, and reduce the workload of ECG signal classification.
DeepRhythmAI is not intended for use in life-supporting or sustaining systems or ECG alarm devices, and its interpretation results are not meant to be the sole means of diagnosis. It functions as an advisory tool, providing supportive information for review in conjunction with a physician's clinical judgment.
Yes, other AI-ECG platforms exist for ambulatory recording analysis, such as Cardiologs and BeatLogic. Additionally, modern alternatives to traditional Holter monitoring include wearable ECG devices, patch monitors, implantable loop recorders, and remote patient monitoring (RPM) platforms.
DeepRhythmAI has demonstrated superior accuracy, achieving 98.6% sensitivity for critical arrhythmias compared to 80.3% for human technicians, and a 99.9% negative predictive value for ruling out critical arrhythmias. This translates to a significantly lower rate of missed diagnoses.
Medicalgorithmics offers DeepRhythmAI on a subscription basis, but specific pricing details require contacting the vendor directly.

Compare DeepRhythmAI

VS
DeepRhythmAI vs PMcardio
Cardiology AI Direct · 90/100
DeepRhythmAI and PMcardio are direct competitors, both offering AI-powered ECG analysis for cardiac arrhythmia detection and classification. DeepRhythmAI focuses on revolutionizing diagnostics with superior accuracy and efficiency for…
VS
DeepRhythmAI vs Sleepiz One+
Cardiology AI Adjacent · 65/100
DeepRhythmAI is an AI algorithm focused on highly accurate and efficient detection and classification of cardiac arrhythmias from ECG data, primarily for diagnostic purposes. Sleepiz One+ is a…
VS
DeepRhythmAI vs Cardiomo
Cardiology AI Adjacent · 65/100
DeepRhythmAI is a cloud-based AI algorithm focused on highly accurate and efficient cardiac arrhythmia detection and classification from existing ECG data for clinical use. Cardiomo, while also utilizing…
VS
DeepRhythmAI vs EchoNext
Cardiology AI Adjacent · 75/100
DeepRhythmAI and EchoNext are adjacent competitors, both leveraging AI for ECG analysis in cardiology. DeepRhythmAI focuses on detecting and classifying cardiac arrhythmias, aiming to improve efficiency and accuracy…

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.